目的：探讨自体树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）联合常规化疗治疗转移性胰腺癌患者的近、远期效果。方法：选取96例转移性胰腺癌患者随机分为对照组与观察组，每组各48例，对照组患者行单纯替吉奥化疗，观察组在替吉奥化疗的基础上联合使用自体DC-CIK治疗，比较两组的近期（两个疗程后）疗效与远期预后。结果：对照组与观察组的缓解率差异无统计学意义（39.58% vs. 27.08%，P>0.05），但总有效率明显升高（77.08% vs. 58.33%，P<0.05）；两组治疗前T淋巴细胞亚群、IFN-γ与IL-4水平差异均无统计学意义（均P>0.05），治疗后，观察组CD3+细胞、CD4+细胞、CD4+/CD8+比值、IFN-γ水平明显高于对照组（P<0.05），CD8+细胞、IL-4水平明显低于对照组（P<0.05）。两组患者的治疗过程中各毒副反应的发生率无明显差异（均P>0.05）。观察组患者平均生存期与1、2、3年生存率均明显高于对照组（15.0个月 vs. 10.0个月；66.67%、29.17%、8.33% vs. 43.75%、10.42%、0，均P<0.05）。结论：自体DC-CIK联合常规化疗对转移性胰腺癌患者近期疗效、远期预后均具有改善作用。
Efficacy of combination of autologous dendritic cells-cytokine induced killer cells with conventional chemotherapy for metastatic pancreatic cancer
Objective: To investigate the short- and long-term effects of the combination of autologous dendritic cells-cytokine induced killer cells (DC-CIK) with conventional chemotherapy in treatment of metastatic pancreatic cancer. Methods: Ninety-six patients with metastatic pancreatic cancer were selected and randomly divided into control group and observation group, with 48 cases in each group. Patients in control group underwent the chemotherapy regimen of S-1 (tegafur/gimeracil/oteracil), while those in observation group received autologous DC-CIK transfusions based on S-1 chemotherapy. The short-term (two courses later) efficacy and long-term prognosis of the two groups of patients were compared. Results: In observation group compared with control group, the response rate showed no significant difference (39.58% vs. 27.08%, P>0.05), while the total disease-control rate was significantly increased (77.08% vs. 58.33%, P<0.05); there were no significant differences in T-lymphocyte subsets and levels of IFN-γ+, CD4+, between the two groups before treatment (all P>0.05), but the CD3+ and CD4+ cells, CD4+/CD8+ ratio and IFN-γ level were significantly higher, the CD8+ cells and IL-4 level was significantly lower than those in control group after treatment (all P<0.05). No significant differences were noted in the incidence of adverse reactions between the two groups of patients during treatment (all P>0.05). The average survival time as well as 1-, 2-, and 3-year survival rates in observation group were all significantly better in observation group than those in control group (15.0 months vs. 10.0 months; 66.67%, 29.17% and 8.33% vs. 43.75%, 10.42% and 0, all P<0.05). Conclusion: Autologous DC-CIK transfusions combined with conventional chemotherapy has improving effects on both short-term effect and long-term prognosis in patients with metastatic pancreatic cancer.